

5

溫

2 FINANCIAL SUMMARY

2.1 PRINCIPAL FINANCIAL DATA AND INDICATORS

	For the six months ended June 30,	
	2019 <i>RMB'000</i> (Unaudited)	2018 <i>¥'000</i> ()
-	378,910	356,778
	52,661	59,108
	(7,120)	(18,256)
	45,541	40,852
	52,064	41,987
	(6,523)	(1,135)
	As at	
	June 30, 2019 <i>(RMB'000)</i> (Unaudited)	June 31, 2018 <i>(¥'000)</i> (A)
-	2,010,230	1,840,724
	751,355	635,451
	1,258,875	1,205,273
	1,158,252	1,120,995
-	100,623	107,087

3 BUSINESS REVIEW AND OUTLOOK

[illegible]

4.1 Financial Review

4.1.1 Revenue and Cost of Revenue

$$\vdots$$
4

		For the six months ended June 30,	
		2019	2018
		(Unaudited)	(T)
Inpatients		5,593	4,180
	-	1,012,333	756,580

	For the six months ended June 30,	
	2019 (RMB'000) (Unaudited)	2018 (RMB'000) (Unaudited)
	101,813	80,594
	91,091	66,324
	—	12,287
	14,119	
	30,236	21,962
	16,577	12,640
	7,807	7,002
	18,290	13,695
Cost of revenue for owned hospitals	279,933	214,504
	279.9	30.5%
	2018,	
	: ()	
	26.3%; ()	
	37.3%	
	; ()	
14.9%		2018; ()
	37.7%	2018,
		36.4% (
	30, 2018: 37.6%),	
		;
		32.5%
(	30, 2018: 30.9%);	
		15.8% (
	30, 2018: 16.0%).	

For the six months ended June 30,	
2019 (RMB'000) (Unaudited)	2018 (RMB'000) (Unaudited)
12,800	12,107
6,073	6,361
<u>6,727</u>	<u>5,746</u>

12.8% increase, compared with 5.7% increase in 2018, (3.4% decrease, compared with 3.5% increase in 2018).

6.1% increase, compared with 52.6% increase in 2018 (47.5% increase).

3.4% increase, compared with 1.1% increase in 2018.

4.1.2 Gross Profit and Gross Profit Margin

2018. 28.9% 92.0 28.9% 87.0 2018. :

	For the six months ended June 30,	
	2019 (Unaudited)	2018 (Audited)
Operating profit margin	25.1%	40.9%
Operating expense ratio	14.5%	16.8%
Operating profit	52.6%	47.5%
Operating loss	23.3%	35.7%
Operating income	85.2%	51.6%
Consolidated gross profit margin	24.3%	36.3%

24.3%
15.8
2018,
-
;
2.3
2018,
,
1, 2019.

4.1.3 Tax and Surcharge

(, 30, 2018: 3.4), 0.8

2019.

4.1.4 Selling Expenses

(, 30, 2018: 2.6), 4.5
2018,
, .
1.2% , (30, 2018: 0.7%).

4.1.5 Administrative Expenses

	,	,	,	.
,	,			
:				

**For the six months
ended June 30,
2019 2018
(RMB'**

	For the six months ended June 30,	
	2019	2018
	(RMB'000)	(US\$'000)
	(Unaudited)	(Unaudited)
Interest income	1,925	1,963
Interest expense	(759)	(355)
Net interest income	(3,520)	(4,135)
Net interest income	(5,706)	
Net interest income	(1,841)	(2,750)
Net interest income	(298)	(253)
Finance expenses – Net	(10,199)	(5,530)

4.2 Financial Position

4.2.1 Inventory

A 30, 2019, 23.5 (

31, 2018: 20.8), : ()

(A .) (.) 11,850.34

T

- , 29, 2043,

4.2.5 Other Non-current Financial Assets

A 30, 2019, 51.0
(31, 2018: 51.0).

4.2.6 Right-of-use Assets

A 30, 2019, - - 262.9 (31, 2018:),

4.2.7 Accounts Payables

A 30, 2019, 53.3 (31, 2018: 73.6),

4.2.8 Contract Liability

A 30, 2019, 9.1 (31, 2018: 2.2).

4.2.9 Other Payables

A 30, 2019, 119.0 (31, 2018: 129.8),

S

S

S

4.3 Liquidity and Capital Resources

:

For the six months ended June 30,	
2019	2018
(RMB'000)	('000)
(Unaudited)	(Unaudited)
4,157	25,390
(75,880)	(132,285)
(25,941)	25,735
(98,423)	(81,439)

4.3.1 Net Cash Generated from Operating Activities

▲	4.2	,	▲	45.5
฿	39.2	,	฿	72.2
				-
▲	20.8	.		
฿			฿	

4.3.2 Net Cash Used in Investing Activities

	,	▲	63.0	▲	75.9
	,				,
	,				
;		▲	13.0		
	.				

4.3.3 Net Cash Used in Financing Activities

▲	25.9	,		▲	47.4	,
฿				฿	24.0	.

4.3.4 Significant Investment, Acquisition and Disposal

☒ 30, 2019.

4.4 Indebtedness

4.4.1 Bank Borrowings

A ☒ 30, 2019, (31, 2018: ▲ 225.0),
 ▲ 170.0
 ฿ 249.0
 ฿ 146.0

4.4.2 Contingent Liabilities

4.4.4 Lease Liabilities

As at 30, 2019, the Company's lease liabilities were \$191.3 million, compared to \$191.3 million as at 30, 2018. The Company's lease liabilities are classified as non-current liabilities.

4.4.5 Financial Instruments

The Company's financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and other financial instruments. The Company's financial instruments are classified as current assets and liabilities.

4.4.6 Exposure to Fluctuation in Exchange Rates

The Company's operations are primarily conducted in the United States, and the Company's financial statements are presented in US dollars. The Company's exposure to fluctuation in exchange rates is limited. The Company's financial statements are presented in US dollars, and the Company's operations are primarily conducted in the United States.

4.4.7 Gearing Ratio

As at 30, 2019, the Company's gearing ratio was 37.4%, compared to 31, 2018: 34.5%.

4.4.8 Employees and Remuneration Policy

As at 30, 2019, the Company's total remuneration was \$2,746 million, compared to \$2,581 million as at 30, 2018. The Company's remuneration policy is based on the Company's performance and the performance of its employees. The Company's remuneration policy is based on the Company's performance and the performance of its employees.

5 PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

The Company's purchase, sale and redemption of listed securities are as follows:

6 SUBSEQUENT EVENTS

₩ 30, 2019 ,
.

7 REVIEW OF INTERIM RESULTS

A ,
₩ 30, 2019,
, ,
.

A - , . A
(A), . , .
, .

8 INTERIM DIVIDEND

$\frac{4}{8}$
₩ 30, 2019 (₩ 30, 2018:).

9 COMPLIANCE WITH CG CODE

.

10 ACCOUNTING STANDARDS

A $\frac{4}{8}$
2017, ₩
(622) (
).

11 FINANCIAL REPORT

11.1 Accounting Policies

11.1.1 Accounting Policies

$\frac{4}{8}$ - $\frac{4}{8}$ ₩ A ₩
15, 2006.

. 32 - A $\frac{4}{8}$ ₩
.

11.1.2 Adoption of New Accounting Policies

2018, 2019, 2019.6). 30, 2019 1, 2019. A 2018.

Contents and reasons of the modification of accounting policies	The line items affected	The amounts affected January 1, 2019 The Group
	- -	234,963,917
，		
：		(198,596,521)
，		(26,230,361)
☒ 1, 2019 (	-	
).	- -	
，		(13,968,903)
．		
，		3,831,868
- -		
，		
，		
- -		
，		
．		

11.2 Consolidated Interim Financial Information

11.2.1 Interim Consolidated Statement of Comprehensive Income

		For the six months ended	
		June 30,	
		2019	2018
		RMB	¥
		(Unaudited)	()
1. Revenue		378,910,291	356,778,081
Cost of sales		(286,882,183)	(227,375,436)
Gross profit		(831,972)	(3,375,006)
Selling expenses		(4,476,806)	(2,570,269)
Administrative expenses		(52,890,346)	(50,950,061)
Financial expenses		(2,304,024)	
Other income		(10,198,874)	(5,530,111)
Other expenses		6,567,461	4,253,548
Profit before income tax		23,549,073	(4,318,848)
Income tax		(2,525,317)	(4,318,848)
Profit after income tax		(10,730,916)	(5,742,669)
Other comprehensive income		—	(1,160,929)
Comprehensive income		(18,587)	(6,378)
2. Operating profit		40,693,117	60,001,922
Other income	-	26,438,682	1,197,342
Other expenses	-	(14,470,650)	(2,091,319)
3. Total profit		52,661,149	59,107,945
Other comprehensive income		(7,119,918)	(18,256,405)

		For the six months ended June 30,	
		2019	2018
		RMB	¥
		(Unaudited)	(Unaudited)
4. Net profit		<u>45,541,231</u>	<u>40,851,540</u>
		45,541,231	40,851,540
		-	
5. Total comprehensive income	5	<u>45,541,231</u>	<u>40,851,540</u>
		52,064,124	41,986,854
		(6,522,893)	(1,135,314)

11.2.2 Interim Consolidated Statement of Financial Position

ASSETS	June 30, 2019 RMB (Unaudited)	31, 2018 RMB (A)
Current assets		
	88,643,935	187,076,694
A	343,085,203	299,750,063
	63,601,330	58,051,581
A	6,773,294	16,683,839
	23,496,443	20,813,747
-	12,688,704	12,688,704
Total current assets	538,288,909	595,064,628
Non-current assets		
-	50,974,323	50,974,323
-	84,166,020	100,321,983
	138,214,682	128,568,963
	429,798,060	444,322,834
	128,365,125	131,187,406
- -	262,857,848	—
	119,723,596	185,257,977
	47,503,344	19,296,005
-	159,645,805	144,386,669
	47,483,569	33,825,347
-	3,209,169	7,517,900
Total non-current assets	1,471,941,541	1,245,659,407
TOTAL ASSETS	2,010,230,450	1,840,724,035

LIABILITIES AND OWNERS' EQUITY	June 30, 2019 RMB (Unaudited)	31, 2018 ¥ (A)
Current liabilities		
-	170,000,000	145,000,000
\$A	53,319,851	73,644,717
	9,139,823	2,244,706
	19,877,674	28,270,410
	36,365,584	41,119,676
	118,956,827	129,807,988
-	84,786,940	63,757,304
Total current liabilities	492,446,699	

11.2.3 Interim Consolidated Statements of Cash Flow

For the six months

		For the six months ended June 30,	
		2019	2018
		RMB	¥
		(Unaudited)	(Unaudited)
3. Cash flows from financing activities		4,245,000	4,430,000
:			
-		4,245,000	4,430,000
		170,000,000	170,000,000
Sub-total of cash inflows		174,245,000	174,430,000
		(146,000,000)	(139,791,600)
		(6,647,896)	(5,934,843)
		(47,538,263)	(2,968,171)
Sub-total of cash outflows		(200,186,159)	(148,694,614)
Net cash flows generated from financing activities		(25,941,159)	25,735,386
4. Effect of changes in foreign exchange rate		(758,597)	(279,073)
5. Net decrease in cash and cash equivalents		(98,422,759)	(81,439,042)
A :		187,066,694	237,538,659
6. Cash and cash equivalents at end of the period		88,643,935	156,099,617

11.2.4 Interim Consolidated Statement of Changes In Equity

	Equity attributable to owners of the parent company						Total owners' equity
	Share capital	Capital surplus	Less: treasury stock	Surplus reserve	Retained earnings	Non-controlling interests	
Balance at January 1, 2019	75,500,000	827,379,886	(21,910,000)	29,981,034	210,044,608	84,277,828	1,205,273,356
	-	-	-	-	52,064,124	(6,522,893)	45,541,231
	-	-	-	-	-	4,245,000	4,245,000
5 -	-	2,688,937	-	-	-	-	2,688,937
	-	(12,255)	-	-	(1,452,916)	245,168	(1,220,003)
5	-	(130,000)	130,000	-	-	(2,040,163)	(2,040,163)
4	-	(4,705,722)	-	-	-	-	(4,705,722)
8	-	-	-	-	-	20,417,809	20,417,809
	-	-	-	-	(11,325,000)	-	(11,325,000)
Balance at June 30, 2019	<u>75,500,000</u>	<u>825,220,846</u>	<u>(21,780,000)</u>	<u>29,981,034</u>	<u>249,330,816</u>	<u>100,622,749</u>	<u>1,258,875,445</u>

	Equity attributable to owners of the parent company					Total owners' equity
	Share capital	Capital surplus	Surplus reserve	Retained earnings	Non-controlling interests	
Balance at December 31, 2017	73,040,000	808,244,186	23,710,012	146,840,254	58,662,363	1,110,496,815
A :				(164,301)		(164,301)
Balance at January 1, 2018	73,040,000	808,244,186	23,710,012	146,675,953	58,662,363	1,110,332,514
				41,986,854	(1,135,314)	40,851,540
					4,730,000	4,730,000
5 -		206,400				206,400
5		910,596				910,596
				(10,956,000)		(10,956,000)
Balance at June 30, 2018	<u>73,040,000</u>	<u>809,361,182</u>	<u>23,710,012</u>	<u>177,706,807</u>	<u>62,257,049</u>	<u>1,146,075,050</u>

11.3 Notes to the Consolidated Interim Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

11.3.1 Accounts receivable

		June 30, 2019 RMB (Unaudited)	31, 2018 RMB (A)
A		6,750,000	6,749,917
A	-	366,111,251	318,519,503
5	:	372,861,251	325,269,420
		(29,776,048)	(25,519,357)
		<u>343,085,203</u>	<u>299,750,063</u>

31, 2018 : 30, 2019

		June 30, 2019 RMB (Unaudited)	31, 2018 RMB (A)
1		286,466,031	261,000,854
1 - 2		73,454,874	51,396,190
2 - 3		10,456,002	12,862,881
3		2,484,344	9,495
		<u>372,861,251</u>	<u>325,269,420</u>

A ,

11.3.2 Accounts payable

30, 2019

31, 2018

•

June 30, 2019 <i>RMB</i> <i>(Unaudited)</i>	31, 2018 <i>B</i> <i>(A)</i>
--	---------------------------------------

$$\begin{array}{r} 3 \\ 3 - 6 \\ 6 \quad - 1 \\ 1 - 2 \\ 2 - 3 \\ 3 \end{array}$$

47,578,421	43,099,493
4,026,068	3,971,590
1,370,483	836,832
102,513	25,470,222
50,497	50,357
191,869	216,223
53,319,851	73,644,717

Revenue and cost of sales from main operations

For the six months ended June 30, 2019	
<i>RMB</i> (Unaudited)	<i>RMB</i> (Unaudited)
Revenue from main operations	Cost of revenue from main operations
96,629,883	82,628,810
263,579,519	197,304,478
12,800,139	6,073,089
<u>373,009,541</u>	<u>286,006,377</u>

30, 2018
 () ()

78,253,106	65,087,164
252,958,034	149,416,996
12,107,112	6,360,903
<u>343,318,252</u>	<u>220,865,063</u>

11.3.4 Earnings per share

() 4
B

For the six months ended June 30,	
2019	2018
RMB	B
(Unaudited)	()
52,064,124	41,986,854
73,040,000	73,040,000
0.71	0.57

4
B

()

30, 2019,

4
B 52,064,124,
B 73,915,743
0.70. 30,

2018,

. A ,

11.3.5 Income tax expenses

For the six months ended June 30,	
2019	2018
RMB	B
(Unaudited)	()
14,824,769	20,483,722
(7,704,851)	(2,227,317)
7,119,918	18,256,405

:

**For the six months ended
June 30,
2019**

院有限公司), .. (冠縣怡寧醫
1, 2017,
S ()
S ,
4 1.00 ,
B S
S
..
(杭州耶利米信息科技有限公司),
27, 2018,
.. (杭州怡寧醫
院有限公司), A 25, 2016,
-
.. (荷澤
怡寧神病醫院有限公司,
.. (荷澤怡寧醫院有限公司)),
A 6, 2017,
-
S A
S ,
S
S
S
.. (淮南康寧醫院
有限公司), 22, 2017,
S -
.. (廊坊怡寧醫
院有限公司),
.. (廊坊市怡寧醫院
管理有限公司)),
2, 2015,
S

橋慈寧醫院有限公司, .. (台州市路
院有限公司)), .. (台州市路橋怡寧醫

5

公司), .. (四會康寧醫院有限
A 19, 2016,
,

公司) 10, 2019 .. (廣東肇康醫療投資有限

(622)

院有限公司), .. (台州康寧醫
30, 2016,
,

.. (溫嶺南方精神疾病專科醫院有限公司),
20, 2018, , -

5

限公司), .. (溫州慈寧醫院有
25, 2006

投資有限公司), .. (溫州國大
9, 2002,
,

26, 2015

(廊坊三河燕郊輔仁醫院,

燕郊輔仁中西醫結合醫院)

有限公司), .. (永嘉康寧醫院
12, 2012,
,

%

4B

4B

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili

A 26, 2019

A . A ; - , A . A ; . A .
- . , . A .